FDA Authorizes Broad Use Of Tamiflu And Relenza To Deal With Swine Flu Outbreak
This article was originally published in The Pink Sheet Daily
Executive Summary
Emergency Use Authorizations for Roche and GSK products facilitate distribution to wider population, including alternate dosing or use by individuals outside approved labeling. FDA’s Sharfstein testifies before Congress April 30.
You may also be interested in...
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
H1N1 Vaccine Update: Big Sales To Come In Fourth Quarter, Mfrs. Say
The pandemic influenza situation is leaving the biopharmaceutical industry in a healthy state - with early reports of vaccine sales having notable impact on manufacturers' bottom lines, revitalization for waning antiviral products and accelerated pathways for novel products
Flu Vaccine Licensure Depends On Adjuvant; Fall Vaccination Campaign Likely
Efforts are under way to expedite H1N1 vaccine development for a potential voluntary vaccine campaign in the fall, but how registration of the vaccine is handled by FDA depends on whether or not an adjuvant is used